Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial.

Parsons SN, Luzio SD, Harvey JN, Bain SC, Cheung WY, Watkins A, Owens DR.

Diabet Med. 2019 May;36(5):578-590. doi: 10.1111/dme.13899. Epub 2019 Feb 18.

PMID:
30653704
2.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB.

Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607.

PMID:
30520217
3.

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.

Owens DR, S Bailey T, Fanelli CG, Yale JF, Bolli GB.

Diabetes Metab. 2018 Nov 26. pii: S1262-3636(18)30219-2. doi: 10.1016/j.diabet.2018.11.004. [Epub ahead of print] Review.

PMID:
30496834
4.

Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.

Frier BM, Landgraf W, Zhang M, Bolli GB, Owens DR.

Diabetes Obes Metab. 2018 Dec;20(12):2894-2898. doi: 10.1111/dom.13450. Epub 2018 Jul 22.

PMID:
29943493
5.

Recombinant Human Insulin in Global Diabetes Management - Focus on Clinical Efficacy.

Mbanya JC, Sandow J, Landgraf W, Owens DR.

Eur Endocrinol. 2017 Apr;13(1):21-25. doi: 10.17925/EE.2017.13.01.21. Epub 2017 Apr 3. Review.

6.

The application of simple metrics in the assessment of glycaemic variability.

Monnier L, Colette C, Owens DR.

Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6. Review.

PMID:
29602622
7.

Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.

Currie CJ, Holden SE, Owens DR.

Curr Med Res Opin. 2017 Oct;33(sup2):33-43. doi: 10.1080/03007995.2017.1366662. Epub 2017 Sep 7.

PMID:
28881150
8.

Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.

Holden SE, Currie CJ, Owens DR.

Curr Med Res Opin. 2017 Oct;33(sup2):5-17. doi: 10.1080/03007995.2017.1366645. Epub 2017 Sep 7.

PMID:
28881149
9.

Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema.

Holden SE, Currie CJ, Owens DR.

Curr Med Res Opin. 2017 Oct;33(sup2):45-52. doi: 10.1080/03007995.2017.1366663. Epub 2017 Sep 7.

PMID:
28881146
10.

Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.

Currie CJ, Holden SE, Berni E, Owens DR.

Curr Med Res Opin. 2017 Oct;33(sup2):19-31. doi: 10.1080/03007995.2017.1366659. Epub 2017 Sep 7.

PMID:
28881143
11.

Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015.

Thomas RL, Luzio SD, North RV, Banerjee S, Zekite A, Bunce C, Owens DR.

BMJ Open. 2017 Jul 18;7(7):e015024. doi: 10.1136/bmjopen-2016-015024.

12.

A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Owens DR, Monnier L, Hanefeld M.

Diabetes Obes Metab. 2017 Dec;19(12):1645-1654. doi: 10.1111/dom.12998. Epub 2017 Jul 11. Review.

13.

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.

Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A.

Diabetes Obes Metab. 2017 Nov;19(11):1546-1554. doi: 10.1111/dom.12966. Epub 2017 Jul 27.

PMID:
28449412
14.

Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.

Owens DR, Monnier L, Barnett AH.

Diabetes Obes Metab. 2017 Oct;19(10):1339-1352. doi: 10.1111/dom.12977. Epub 2017 Jun 9. Review.

15.

Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial.

Parsons S, Luzio S, Bain S, Harvey J, McKenna J, Khan A, Rice S, Watkins A, Owens DR.

BMC Endocr Disord. 2017 Jan 26;17(1):4. doi: 10.1186/s12902-017-0154-x.

16.
17.

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.

Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N, Owens DR.

Diabetes Care. 2017 Jul;40(7):832-838. doi: 10.2337/dc16-1769. Epub 2016 Dec 30.

PMID:
28039172
19.

Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials.

Inagaki N, Sheu WH, Owens DR, Crowe S, Bhandari A, Gong Y, Patel S.

J Diabetes Complications. 2016 Nov - Dec;30(8):1622-1630. doi: 10.1016/j.jdiacomp.2016.07.002. Epub 2016 Jul 15.

PMID:
27499458
20.

Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.

Owens DR.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):977-87. doi: 10.1080/17425255.2016.1202916. Review.

PMID:
27453980
21.

When should screening for diabetic retinopathy begin for children with type 1 diabetes?

Thomas RL, Harvey JN, Owens DR.

Expert Rev Endocrinol Metab. 2016 Mar;11(2):97-102. doi: 10.1586/17446651.2016.1145542. Epub 2016 Feb 12. No abstract available.

PMID:
30058865
22.

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Monnier L, Colette C, Dejager S, Owens DR.

Rev Endocr Metab Disord. 2016 Mar;17(1):91-101. doi: 10.1007/s11154-016-9325-8. Review.

PMID:
26803295
23.

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.

Monnier L, Owens DR, Bolli GB.

Diabetes Metab. 2016 Apr;42(2):77-9. doi: 10.1016/j.diabet.2015.11.005. Epub 2015 Dec 10. No abstract available.

PMID:
26688145
24.

Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β-Cell Function.

Roy Chowdhury S, Thomas RL, Dunseath GJ, Peter R, Rees DA, North RV, Luzio SD, Owens DR.

J Clin Endocrinol Metab. 2016 Feb;101(2):572-80. doi: 10.1210/jc.2015-2203. Epub 2015 Dec 11.

PMID:
26652932
25.

Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.

Lankisch MR, Del Prato S, Dain MP, Mullins P, Owens DR.

Prim Care Diabetes. 2016 Feb;10(1):51-9. doi: 10.1016/j.pcd.2015.05.003. Epub 2015 Jul 4.

26.

"Mild dysglycemia" in type 2 diabetes: to be neglected or not?

Monnier L, Colette C, Dejager S, Owens DR.

J Diabetes Complications. 2015 Apr;29(3):451-8. doi: 10.1016/j.jdiacomp.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25572605
27.

New Meta-Analysis of Patient-Level Data on Efficacy And Hypoglycaemia with Insulin Glargine or Nph Insulin in Type 2 Diabetes Mellitus (T2DM) According to Concomitant Oral Therapy.

Owens DR, Trayor L, Landgraf W, Mullins P.

Value Health. 2014 Nov;17(7):A335. doi: 10.1016/j.jval.2014.08.644. Epub 2014 Oct 26. No abstract available.

28.

Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.

Chan JC, Aschner P, Owens DR, Picard S, Vincent M, Dain MP, Pilorget V, Loizeau V, Echtay A, Fonseca V.

J Diabetes Complications. 2015 Jan-Feb;29(1):134-41. doi: 10.1016/j.jdiacomp.2014.08.007. Epub 2014 Aug 27.

29.

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

Owens DR, Traylor L, Dain MP, Landgraf W.

Diabetes Res Clin Pract. 2014 Nov;106(2):264-74. doi: 10.1016/j.diabres.2014.08.003. Epub 2014 Aug 12.

30.

Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service.

Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, Gibbins RL, Owens DR.

Br J Ophthalmol. 2015 Jan;99(1):64-8. doi: 10.1136/bjophthalmol-2013-304017. Epub 2014 Aug 4.

PMID:
25091950
31.

The evolution of insulin glargine and its continuing contribution to diabetes care.

Hilgenfeld R, Seipke G, Berchtold H, Owens DR.

Drugs. 2014 Jun;74(8):911-27. doi: 10.1007/s40265-014-0226-4. Review.

32.

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2014 Jun;16(6):560-8. doi: 10.1111/dom.12281. Epub 2014 Mar 24.

33.

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.

Bolli GB, Owens DR.

Diabetes Obes Metab. 2014 Jul;16(7):588-601. doi: 10.1111/dom.12253. Epub 2014 Jan 20. Review.

PMID:
24373190
34.

Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study.

Thomas RL, Prior SL, Barry JD, Luzio SD, Eyre N, Caplin S, Stephens JW, Owens DR.

J Diabetes Complications. 2014 Mar-Apr;28(2):191-5. doi: 10.1016/j.jdiacomp.2013.10.006. Epub 2013 Oct 23.

PMID:
24332764
35.

Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study.

Morgan CL, Owens DR, Aubonnet P, Carr ES, Jenkins-Jones S, Poole CD, Currie CJ.

BMJ Open. 2013 Dec 3;3(12):e004025. doi: 10.1136/bmjopen-2013-004025.

36.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
37.

A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.

Luzio SD, Dunseath GJ, Atkinson MD, Owens DR.

Diabetes Metab. 2013 Dec;39(6):537-42. doi: 10.1016/j.diabet.2013.09.002. Epub 2013 Oct 17.

PMID:
24139704
38.

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?

Owens DR, Matfin G, Monnier L.

Diabetes Metab Res Rev. 2014 Feb;30(2):104-19. doi: 10.1002/dmrr.2469. Review.

PMID:
24026961
39.

Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes.

Peter R, Dunseath G, Luzio SD, Owens DR.

Diabetes Metab. 2013 Sep;39(4):337-42. doi: 10.1016/j.diabet.2013.07.001. Epub 2013 Aug 30.

PMID:
23993831
40.

Does feeding by Halyomorpha halys (Hemiptera: Pentatomidae) reduce soybean seed quality and yield?

Owens DR, Herbert DA Jr, Dively GP, Reisig DD, Kuhar TP.

J Econ Entomol. 2013 Jun;106(3):1317-23.

PMID:
23865197
41.

Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes.

Owens DR.

Diabetes Technol Ther. 2013 Sep;15(9):776-85. doi: 10.1089/dia.2013.0081. Epub 2013 Jun 20. Review.

42.

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.

J Diabetes Complications. 2013 May-Jun;27(3):274-9. doi: 10.1016/j.jdiacomp.2012.11.008. Epub 2013 Feb 9.

PMID:
23403068
43.

Glargine and cancer: can we now suggest closure?

Owens DR.

Diabetes Care. 2012 Dec;35(12):2426-8. doi: 10.2337/dc12-1968. No abstract available.

44.

The emergence of biosimilar insulin preparations--a cause for concern?

Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK.

Diabetes Technol Ther. 2012 Nov;14(11):989-96. doi: 10.1089/dia.2012.0105. Epub 2012 Oct 9. Review.

45.

Response letter to D. Singh-franco et al.

Owens DR, Del Prato S, Taskinen MR, Gomis R, Forst T, Woerle HJ.

Diabetes Obes Metab. 2012 Nov;14(11):1054-5. doi: 10.1111/j.1463-1326.2012.01623.x. No abstract available.

PMID:
23034010
46.

Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa.

Thomas RL, Distiller L, Luzio SD, Chowdhury SR, Melville VJ, Kramer B, Owens DR.

Diabetes Care. 2013 Feb;36(2):336-41. doi: 10.2337/dc12-0683. Epub 2012 Oct 1.

48.

Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.

Nosek L, Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, Fischer A, Heise T.

Diabetes Obes Metab. 2012 Dec;14(12):1137-44. doi: 10.1111/dom.12003. Epub 2012 Sep 25.

PMID:
22988932
49.

Optimizing treatment strategies with insulin glargine in Type 2 diabetes.

Owens DR.

Expert Rev Endocrinol Metab. 2012 Jul;7(4):377-393. doi: 10.1586/eem.12.29.

PMID:
30754169
50.

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.

Gomis R, Owens DR, Taskinen MR, Del Prato S, Patel S, Pivovarova A, Schlosser A, Woerle HJ.

Int J Clin Pract. 2012 Aug;66(8):731-740. doi: 10.1111/j.1742-1241.2012.02975.x. Epub 2012 Jun 12.

PMID:
22691164

Supplemental Content

Loading ...
Support Center